| Objective: To evaluate the efficacy of resveratrol in the treatment of non-alcoholic fatty liver disease.Methods: PubMed,EMBASE,Web of Science,The Cochrane Central Register of Controlled Trials,Database for Chinese Technical Periodical(VIP),Chinese Journal Full-Text Database(CNKI),and Wan Fang Digital Journal Full-text Database were retrieved to collect clinical randomized controlled trials of non-alcoholic fatty liver disease patients treated by resveratrol without year restrictions.Resveratrol was used in the treatment group and placebos were used in the control group.Meta analysis was performed by using Stata 12.0 software.Results: Six articles controlled trials including 218 patients met the inclusion criteria.Meta-analysis results were as follows.(1)The resveratrol was associated with a significant reduction in AST(WMD=-4.562,95%CI :-6.744~-2.380,P = 0.000)compared with the placebo.(2)The resveratrol was associated with a significant reduction in triglyceride(WMD=-0.326,95%CI:-0.430~-0.222,P = 0.000)compared with the placebo.(3)The resveratrol led to more significant reduction in blood glucose(WMD=–0.252,95%CI:–0.401~-0.103,P=0.001)than the placebo.(4)The resveratrol led to more significant reduction in IL-6(WMD=-4.816,95%CI:-8.585~-1.047,P = 0.012)and CRP(WMD=-0.618,95%CI:-1.071~-0.166,P = 0.007)than the placebo.(5)The effective rate of the resveratrol to reduce SBP(WMD=-5.972,95%CI:-9.069~-2.875,P = 0.000),DBP(WMD=-3.615,95%CI:-6.426~-0.805,P = 0.012)and WC(WMD=-4.983,95%CI:-6.054~-3.913,P = 0.000)in patients of the treatment group was significantly greater than in patients of the control group.Conclusions: Resveratrol can improve partial liver enzymes,glucose metabolism,and lipid metabolism,and anthropometric index in patients with NAFLD,and may be a new option for NAFLD treatment. |
